Cargando…
IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell
Drug discovery research to fight lung cancer is incessantly challenged by drug resistance. In this study, we used drug-resistant lung cancer stem like cells (A549-CS) to compare the efficacy of standard drugs like cisplatin (DDP) and gemcitabine (GEM) with a novel arylidene derivative IOX-101. A549-...
Autores principales: | Fayi, Majed Al, Alamri, Ahmad, Rajagopalan, Prasanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851539/ https://www.ncbi.nlm.nih.gov/pubmed/31771696 http://dx.doi.org/10.3727/096504019X15746768080428 |
Ejemplares similares
-
Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways
por: Sahin, K., et al.
Publicado: (2012) -
CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways
por: Liu, Lu, et al.
Publicado: (2021) -
Computational docking and in vitro analysis identifies novel arylidene analogue FPMXY-14 against renal cancer cells by attenuating Akt
por: OTIFI, HASSAN M., et al.
Publicado: (2022) -
Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020) -
Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)